ADAPTIMMUNE THERAPEUTICS PLC

Analyst Reco. Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
1.15 ^USD	+6.98%		+13.86%	+45.02%

04-29	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	MT
04-24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Adjusts Adaptimmune Therapeutics Price Target to $1 From $2, Maintains Underweight Rating	23-08-10	MT
EF Hutton Initiates Adaptimmune Therapeutics at Buy With $10 Price Target	23-01-05	MT
Guggenheim Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $5	23-01-03	MT
Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $3 From $1.50, Maintains Equal-Weight Rating	22-11-14	MT
Mizuho Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $9	22-11-09	MT
SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $3 from $7, Keeps Market Perform Rating	22-03-15	MT
Barclays Cuts Price Target for Adaptimmune Therapeutics to $2 From $4, Maintains Underweight Rating	22-03-14	MT
ADAPTIMMUNE THERAPEUTICS : Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $7 From $6, Maintains Equal-Weight Rating	21-09-22	MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics PT to $7 From $6, Maintains Market Perform Rating	21-09-13	MT
Adaptimmune Therapeutics plc Announces Clinical Responses Across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation Surpass Trial	21-09-13	CI
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $6 from $5, Keeps Market Perform Rating	21-09-07	MT
ADAPTIMMUNE THERAPEUTICS : Barclays Starts Adaptimmune Therapeutics at Underweight With $4 Price Target	21-05-28	MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerung Adjusts Adaptimmune Therapeutics PT to $6 From $10, Maintains Market Perform Rating	20-11-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer